Special Issue

Translational Theranostics

Guest editor:

Tony Y. Hu Ph.D.
Assistant Professor
Departments of Nanomedicine, Cell and Developmental Biology
The Methodist Hospital Research Institute
Weill Cornell Medical College of Cornell University
6670 Bertner Ave. R8-213
Houston, TX 77030
Tel: 713-441-5530
Email:

The term “theranostics” was coined to define the efforts to develop more specific, individualized therapies for diseases, and to combine diagnostic and therapeutic capabilities into a single system for patients – to test them for possible reaction to taking a new medication and to tailor a treatment for them based on the test results. Theranostics, as a key part of predictive medicine, includes a wide range of subjects, including personalized medicine, pharmacogenomics, and molecular imaging to develop efficient new targeted therapies with adequate benefit/risk to patients and a better molecular understanding of how to optimize drug selection.

Translation theranostics is promoting multidisciplinary interaction between science and medicine to enhance disease research and drug development. In the last decade, medicine has moved to more informed healthcare management and treatment guided by theranostic. The search for markers for disease subtypes and more personalized treatment responses has been accelerated by academic scientists and pharmaceutical companies. A multitude of biomarker candidates have been identified to explain a small fraction of patients’ variations in drug response to therapy or clinical course of the disease. These research initiatives need to be followed by functional studies to determine the molecular mode of action and clinical utility of these markers.

We are editing a special issue for Theranostics on a theme “Translational theranostics”. The focus of this issue is to bring in most recent advances in employing the theranostic platforms with potential to translate to clinic, together with potential of these technologies in diagnosis. We aim to have about 15 research articles and 5 minireviews from leaders in the area of theranostic and translational medicine, while every attempt is being made to generate the highest quality special issue. Topics to be considered include, but are not limited to:

Diagnostic Tests for Translational Research
Cancer Theranostics
Translational Research in Immunology and Infectious Diseases
Cardiology and Disease Management
Blood and Lymph
Molecular Biology in Translational Theranostics
Clinical Epidemiology
Translational Bioinformatics
Nanoparticle Platform for Theranostics
Advances in Translational Theranostics

For more information on the journal and its style, please refer to "Instructions for Authors" at http://www.thno.org/ms/author. The issue is planned for distribution to participants of the International Symposium for Translational Theranostics in Shenzhen, China in May 2014, and will enjoy further prominence at other events and through concerted marketing campaigns. Please note that the issue will only be available after the conference, but it is not a Conference Proceedings. We would highly appreciate if you can confirm your participation at the earliest and provide us the tentative title of your research article or minireview by December 15th, 2013. The manuscript submission DEADLINE is set for February 1st, 2013 and the review process will conclude within 6 weeks from submission, soon after the final decision will be communicated to the authors.

Manuscripts for the special issue can be sent directly to the guest editor(s) by email with the subject "Translational Theranostics Special Issue", or submitted online at http://www.thno.org/ms/submit?subgroup=transthno (mark "Translational Theranostics Special Issue" in the "Suggested reviewers" field to identify the paper).

Detailed formatting instructions, in particular, the formatting of references, can be found in http://www.thno.org/ms/author.

All inquiries should be sent to the guest editor(s) at the above email address.